Abstract PS6-24: Are we missing something? Increased recurrence rates in patients with an oncotype DX score &lt; 26 and a modified magee score &gt; 18: A multi-institutional study
Authors: Turner Bradley M , Gimenez-Sanders Mary Ann , Moisini Ioana , Zhang Huina , Wang Xi , Schiffhauer Linda , Katerji Hani , Skinner Kristin , Gooch Jessica , Shayne Michelle , Ling Marilyn , Falkson Carla , Hicks David 
Published: February 2021

Abstract
INTRODUCTION: Oncotype DX® (ODX) is a multigene assay estimating risk of distant recurrence and chemotherapy benefit in estrogen receptor (ER) positive breast cancer patients. Cost ($4,620.00) impedes its adoption in poorer countries, and the cost is unnecessary in certain patients. TAILORx results suggest that adjuvant endocrine therapy and chemoendocrine therapy had similar efficacy in women with hormone-positive, HER2-negative, node-negative invasive breast carcinomas with an ODX recurrence score &lt; 26. Bhargava et al. and Turner et al. have suggested that a Magee scoreTM or a modified Magee score, respectively, of &lt; 18 will identify patients who are highly likely to have an ODX recurrence score of &lt; 26, and we previously presented data at SABCS 2019 (Abstract P3-07-06) that there is no significant difference in recurrence rate between patients with a modified Magee score of ≤ 18 and patients with an ODX recurrence score &lt; 26 (in preparation for publication). We now present additional recurrence data on patients with a modified Magee score of &gt; 18. METHODS: A total of 301 consecutive patients with ER+ invasive breast cancer from the University of Rochester and the University of Louisville were included in this study, with a mean of 6.6 years of follow-up. All patients had at least 5 years of follow-up (range 5-11 years) except for seven patients , who had a breast cancer recurrence prior to five years. Information on ER, PR, HER-2, Ki-67, Nottingham score , and tumor size were extracted from the pathology report in order to calculate the modified Magee score. Information, on hormone therapy, chemotherapy, radiation therapy, recurrence status, and mortality were extracted from the medical record. For all results, a p-value of &lt; 0.05 was considered significant. RESULTS: 117/301 (39%) patients had a modified Magee score of &gt; 18. The recuurence rate for patients with a modified Magee score &gt; 18 was 11.1%. There was no significant difference in recurrence rate between patients with both a modified Magee score &gt; 18 and ODX recurrence score &lt; 26 compared to patients with both a modified Magee score &gt;18 and ODX recurrence score ≥ 26 (p = 0.547, Table 1). CONCLUSIONS: Patients with a modified Magee score &gt; 18 may be at increased risk for breast cancer recurrence, even if the ODX recurrence score is &lt; 26. Additional studies are necessary to further evaluate these findings.
Table 1: Modified Magee score &gt; 18, Oncotype DX recurrence score (ODXRS), and outcomeRecurrenceNo recurrenceModified Magee score &gt; 18 and ODXRS &lt; 26870Modified Magee score &gt; 18 and ODXRS ≥ 26633
Citation Format: Bradley M Turner, Mary Ann Gimenez-Sanders, Ioana Moisini, Huina Zhang, Xi Wang, Linda Schiffhauer, Hani Katerji, Kristin Skinner, Jessica Gooch, Michelle Shayne, Marilyn Ling, Carla Falkson, David Hicks. Are we missing something? Increased recurrence rates in patients with an oncotype DX score &lt; 26 and a modified magee score &gt; 18: A multi-institutional study [abstract]. In: Proceedings of the 2020 San Antonio Breast Cancer Virtual Symposium; 2020 Dec 8-11; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2021;81(4 Suppl):Abstract nr PS6-24.